1. Epigenetics
    TGF-beta/Smad
    Protein Tyrosine Kinase/RTK
    Stem Cell/Wnt
  2. PKC
    PKA

Staurosporine (Synonyms: Antibiotic AM-2282; STS; AM-2282)

Cat. No.: HY-15141 Purity: 99.98%
Handling Instructions

Staurosporine is a very potent universal inhibitor of protein kinases but showing little selectivity, with IC50 of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase, respectively.

For research use only. We do not sell to patients.
Staurosporine Chemical Structure

Staurosporine Chemical Structure

CAS No. : 62996-74-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO $113 In-stock
2 mg $80 In-stock
5 mg $110 In-stock
10 mg $150 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Staurosporine is a very potent universal inhibitor of protein kinases but showing little selectivity, with IC50 of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase, respectively.

IC50 & Target

IC50: 6 nM/15 nM/2 nM/3 nM (PKC/PKA/c-Fgr/Phosphorylase kinase)[1]

In Vitro

Staurosporine, widely used as a protein kinase C (PKC) inhibitor with a broad spectrum of activity, is an alkaloid isolated from the culture broth of Streptomyces staurospores. MC3T3E-1 osteoblasts, expose to Staurosporine (100 nM) for 12 h, release an amount of LDH (12.4±3.1%) that is similar to that release by the control cells(10.0±2.4%), indicating the relative absence of lytic death, which occurs in necrosis. In addition, treatment with Staurosporine (100 nM) results in morphological changes, characteristic of apoptosis: a brightblue fluorescent condensed nuclei seen through a fluorescence microscope after Hoechst 33258-staining, and a reduction of cell volume[2].

In Vivo

The inhibitory effect of Staurosporine is statistically significant at around Wk 10 of tumor promotion. Although statistically significant inhibition is not obtained with 10 ng of Staurosporine in later weeks of the experiment, a decreasing tendency in the percentages of tumor bearing mice and in average numbers of tumors per mouse is apparent. Thus, Staurosporine slightly inhibits tumor promotion of Teleocidin, even at the dose at which Staurosporine itself induced tumors[3]. Staurosponne (0.05 and 0.1 mg/kg intraperitoneal) attenuates the impaired perlormance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, Staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that Staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion[4].

References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.1435 mL 10.7174 mL 21.4348 mL
5 mM 0.4287 mL 2.1435 mL 4.2870 mL
10 mM 0.2143 mL 1.0717 mL 2.1435 mL
Kinase Assay
[2]

MC3T3E-1 cells (2×106 cells/group) are treated with 100 nM Staurosporine for various time periods and lysed in a lysis buffer (EB buffer: 1% Triton X-100, 10 mM Tris, pH 7.6, 50 mM NaCl, 1 mg/mL Aprotinin, 5 mM EDTA, 50 mM NaF, 0.1% 2-mercaptoethanol, and 100 μM sodium orthovanadate). The lysate of the cells is subjected to centrifugation at 12 000 g at 4°C for 30 min. Soluble fraction is collected and incubated with anti-JNK1 antibodies. After incubation on ice for 3 h, 100 μL of a 10% solution of formalin-fixed Staphylococcus aureus is added to the anti-JNK1 immunoprecipitates and further incubated on ice for 1 h. The absorbed immune complex is washed twice with EB buffer and PAN buffer (10 mM PIPES buffer, pH 7.0, 1% aprotinin, 100 mM NaCl). The immunecomplex is mixed with 2 μg of GST-c-Jun NT1-79 proteins as a substrate in 30 μL of the reaction buffer containing 2 μM cold ATP, 2 mM DTT, 20 mM MgCl2, 2 μCi [γ33-P]-ATP, and 20 mM Tris-HCl, pH 7.5 at 30°C for 20 min. The reaction is terminated by adding 15 μL of 3× SDS-PAGE sample buffer and boiling at 98°C for 5 min. The proteins are separated on 12% SDS-PAGE and transferred onto a nitrocellulose membrane via the semi-dry electrotransfer system. The membrane is immunoblotted with rabbit anti-JNK1 antibodies and horse radish peoxidaseconjugated anti-rabbit antibodies to visualize the signals measured by an enhanced chemiluminescence system. The gel is dried under a vacuum, and the phosphotransferase activity is visualized by autoradiography and quantified by a PhosphoImager analyzer[2].

Animal Administration
[3][4]

Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose (Rat)[4].

Mice[3]
Female CD-I mice are used. Various amounts of Staurosporine in 10 μL of acetone are applied to the ears of 8-wk-old CD-I mice. The extent of irritation is expressed as the minimum dose of the compound causing irritation. Induction of HOC in Mouse Skin Staurosporine in 0.1 mL of acetone is applied to the skin of the backs of CD-I mice, and a crude enzyme extract is obtained from the skin 18 h later. HDC activity is expressed as pmol of CO2 released per mg of protein per l h of incubation. Induction of ODC in Mouse Skin Staurosporine in 0.2 mL of acetone is applied to the skin of the backs of CD-I mice. After 4 h, a crude enzyme extract is prepared from the epidermis, and its ODC activity is measured. Enzyme activity is expressed as nmol of CO2 per mg of protein per 30 min of incubation.
Rats[4]
Male Kbl Wistar rats(weighing 270 to 310 g) are used. In the group which is given Staurosporine for 2 weeks, the water maze task and Staurosporine administration are started 2 weeks after the BF-lesion, and the passive avoidance task is carried out 4 weeks after the BFlesion. The rat received Staurosporine at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg (i.p., N=10 in each group for 2 weeks) 30 mm prior to the water maze training sessions and the passive avoidance task acquisitiontrial. In the group which is given Staurosporine for 4 weeks, the drug is first given 2 weeks after the BF-lesion. The water maze task is carried out 4 weeks after the BF-lesion. The passive avoidance task is carried out 6 weeks after the BF-lesion. The rat received Staurosporine at 0.05, 0.1, and 0.2 mg/kg (i.p., N=10 in each group) once a day for 2 weeks before training, and for 2 weeks after the water maze training sessions and the passive avoidance task acquisition trial. Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose. The vehicle is administered to the non-lesioned controls and the lesioned controls on the same schedule as the Staurosporine-treated animals.

References
M.Wt

466.53

Formula

C₂₈H₂₆N₄O₃

CAS No.

62996-74-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 31 mg/mL

Purity: 99.98%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Staurosporine
Cat. No.:
HY-15141
Quantity: